When.com Web Search

  1. Ads

    related to: winrevair fda approval date for evenity 1 gram of calcium pump

Search results

  1. Results From The WOW.Com Content Network
  2. Sotatercept - Wikipedia

    en.wikipedia.org/wiki/Sotatercept

    Sotatercept, sold under the brand name Winrevair is a medication used for the treatment of pulmonary arterial hypertension. [6] It is an activin signaling inhibitor, [ 6 ] based on the extracellular domain of the activin type 2 receptor expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc). [ 9 ]

  3. US FDA approves Merck's therapy for rare lung condition - AOL

    www.aol.com/news/us-fda-approves-mercks-blood...

    The therapy, branded Winrevair, is approved for treating pulmonary arterial hypertension (PAH), which affects about 40,000 people in the United States. US FDA approves Merck's therapy for rare ...

  4. Why Is Merck Stock Trading Higher On Monday? - AOL

    www.aol.com/why-merck-stock-trading-higher...

    In March, the FDA approved Winrevair for injection for adults with pulmonary arterial hypertension (PAH) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of ...

  5. In March 2024, the FDA approved Winrevair (sotatercept-csrk), for injection, 45mg, 60mg for adults with PAH to increase exercise capacity, improve WHO functional class, and reduce the risk of ...

  6. Romosozumab - Wikipedia

    en.wikipedia.org/wiki/Romosozumab

    Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [7] [8] It has been found to decrease the risk of fractures of the spine. [7] Common side effects include headache, joint pain, and injection site ...

  7. List of drugs granted breakthrough therapy designation

    en.wikipedia.org/wiki/List_of_drugs_granted...

    Treatment of adults with locally advanced, unresectable (stage III) non- small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [2]

  1. Ads

    related to: winrevair fda approval date for evenity 1 gram of calcium pump